Introduction
Androgen deprivation therapy through surgical or medical castration is commonly used as a systemic therapy of advanced prostate cancer because it is initially effective in causing tumor regression and palliating cancer-related symptoms. However, virtually all patients eventually progress and develop hormonerefractory prostate cancer or castration-resistant prostate cancer (CRPC), a terminal disease with poor prognosis. Substantial evidence indicates that androgen receptor (AR) activation in the environment of lowcirculating testosterone has a critical role in the development of CRPC. Studies using xenograft tumor models demonstrate that prostate xenograft tumors that recur after castration express AR-dependent genes (Gregory et al., 1998) . In these cells, the AR protein is stabilized and constitutively localized to the nucleus and is hypersensitive to low levels of androgen (Gregory et al., 2001) . Overexpression of AR enhanced the ability of androgen-dependent prostate xenografts to form tumors in castrated animals, whereas knockdown of AR inhibited their tumorigenicity (Chen et al., 2004) . Multiple mechanisms have been shown to activate AR in CRPC. These include AR gene amplification, increased AR expression, AR point mutations frequently occurring in the ligand-binding domain that broaden ligand specificity, overexpression of AR coactivators and intratumoral production of androgen (Scher and Sawyers, 2005) .
In addition to these mechanisms, AR may be activated by cross talk with signaling pathways initiated by cell surface receptors binding to growth factors, cytokines and neuropeptides. Intracellular pathways involving mitogen-activated protein kinase or phosphatidylinositol 3-kinase/Akt have been proposed to mediate the activation of AR downstream of receptor tyrosine kinases (Gregory et al., 2004; Wang et al., 2007) . For example, epidermal growth factor (EGF) receptor enhances AR transcriptional activity by increasing the interaction between AR and the steroid receptor coactivator TIF (transcriptional intermediary factor)2 secondary to mitogen-activated protein kinasedependent phosphorylation of TIF2 (Gregory et al., 2004) . HER-2 (ErbB2) activates the AR transcriptional function by increasing protein stability, recruitment and DNA binding (Mellinghoff et al., 2004; Liu et al., 2005) . The AR protein is phosphorylated at multiple serine/ threonine residues, and phosphorylation at some of these sites has been proposed to regulate nuclear localization and export (Gioeli et al., 2002 Ponguta et al., 2008) . Recently, several groups have reported that tyrosine phosphorylation of AR protein by non-receptor tyrosine kinases Src and Ack1 (activated cdc42-associated kinase) may have a role in AR activation in the low androgen environment, thereby promoting the development of CRPC (Guo et al., 2006; Kraus et al., 2006; Mahajan et al., 2007) . Src-mediated phosphorylation of AR at Tyr-534 resulted in the activation of AR and nuclear translocation and DNA binding in the absence of androgen (Guo et al., 2006; Kraus et al., 2006) . Our previous work identified Ack1 as a protein activated downstream of Mer receptor tyrosine kinase in prostate cancer cells (Mahajan et al., 2005) . Furthermore, we showed that expression of activated Ack1 increased prostate xenograft tumor growth in castrated animals as well as AR target gene expression and AR recruitment to the enhancers of target genes at suboptimal androgen concentrations (Mahajan et al., 2007) . Ack1 interacted with and phosphorylated AR protein at Tyr-267, and Ack1 was shown to be required for optimal AR target gene expression and AR recruitment. Tyrosine-phosphorylated AR protein was expressed in 8 out of 18 primary CRPC tumor samples, and its expression was correlated with Ack1 activation in the same tumors. In this report, we investigated the upstream signals activating AR phosphorylation, and we showed that Src and Ack1 kinases each contribute to the site-specific phosphorylation of AR.
Results
Site-specific phosphorylation of AR by Ack1 and Src kinases Previous reports have shown that the AR protein may be phosphorylated at Tyr-534 or Tyr-267 residues (Guo et al., 2006; Kraus et al., 2006; Mahajan et al., 2007) . To elucidate signaling pathways leading to AR tyrosine phosphorylation, phospho-specific antibodies against the AR protein phosphorylated at these residues were generated. Their specificity was tested against wild-type and phosphorylation-site mutant AR. Wild-type AR, Y267F AR or Y534F AR expression vectors were cotransfected along with the activated Ack1 or activated Src kinase expression vector. The phospho-Y267-specific antibody detected AR only when Ack1 was coexpressed and did not detect the AR Y267F mutant protein in cell lysates coexpressing Ack1 (Figure 1a) . The phospho-Y534-specific antibody detected AR only when Src was coexpressed and did not recognize the AR Y534F mutant protein in the presence of Src (Figure 1b) . Coexpression of Ack1 led to phosphorylation of Tyr-267, but not Tyr-534 of AR. Conversely, Figure 1 Phospho-specific antibodies show that AR is phosphorylated at Tyr-267 and Tyr-534 after ligand stimulation. (a) 293T cells were transfected with the expression vector encoding wild-type AR or Y267F AR or Y534F AR along with constitutively active Ack1 or empty vector. After 24 h, protein extracts were immunoblotted with the antibody specific for phospho-Y267 AR or total AR. (b) COS7 cells were transfected with the vector encoding wild-type AR or Y267F AR or Y534F AR along with constitutively active Ack1 or activated Src or empty vector, respectively, as indicated. After 24 h, protein extracts were immunoprecipitated with the AR antibody, then immunoblotted with the antibody specific for phospho-Y267 AR or phospho-Y534 AR or total AR, as indicated. (c) LNCaP cells were treated with EGF (100 ng/ml), heregulin (10 ng/ml), Gas6 (100 ng/ml), IL-6 (10 ng/ml) or bombesin (1 nM) for 60 min. Protein extracts were immunoblotted with the antibody specific for phospho-Y267 AR or total AR. (d) LNCaP cells were treated as described above. Protein extracts were immunoprecipitated with the AR antibody, then immunoblotted with the antibody specific for phospho-Y534 AR. Blots shown are representative of three independent experiments. Dasatinib inhibits AR phosphorylation by Ack1 Y Liu et al coexpression of Src resulted in phosphorylation of Tyr-534, but not Tyr-267 of AR. These data suggest that Ack1-and Src-mediated phosphorylation of AR is site specific (that is, Ack1 targets Tyr-267 but not Tyr-534 and vice versa for Src).
Phosphorylation of AR by ligand stimulation
Tyrosine phosphorylation of endogenous AR in prostate cancer cells induced by physiological ligand stimulation was characterized using the phospho-specific antibodies. Extracellular ligands that bind to the cell surface receptors, and have previously been reported to enhance AR activity or may potentially enhance AR activity were tested for their ability to induce AR tyrosine phosphorylation. Gas6 is the ligand for Mer receptor tyrosine kinase, which we have previously shown to activate Ack1 in prostate cells (Mahajan et al., 2005) . Heregulin binds to HER-3 and activates HER-2 kinase through the formation of the HER-2/HER-3 heterodimer. Bombesin (also known as a gastrinreleasing peptide) is a neuropeptide produced by neuroendocrine cells, which has been reported to support growth of androgen-dependent LNCaP cells in an androgen-depleted condition through Src-mediated activation of AR (Desai et al., 2006; Gong et al., 2006; Yang et al., 2009) . Interleukin (IL)-6 leads to ligandindependent activation of the AR N-terminal domain that involves mitogen-activated protein kinase and steroid receptor coactivator-1 (Ueda et al., 2002b) . Treatment of LNCaP cells with EGF, heregulin or Gas6 induced phosphorylation of the AR protein at Tyr-267 ( Figure 1c ). AR phosphorylation was transient and peaked at 60-90 min, and returned to the basal level by 4 h (data not shown). Treatment with IL-6 or bombesin did not induce phosphorylation of the AR at Tyr-267. Phosphorylation of the AR at Tyr-534 was induced by treatment with EGF, IL-6 or bombesin, but not with heregulin or Gas6 (Figure 1d ). EGF was the only ligand tested that induced AR phosphorylation at both Tyr-267 and Tyr-534 sites, in contrast to other ligands that produced site-specific AR phosphorylation (that is, heregulin and Gas6 at Tyr-267 and IL-6 and bombesin at Tyr-534). LAPC-4 prostate cancer cells that express wild-type AR endogenously (Klein et al., 1997) were treated with these ligands, and AR phosphorylation at Tyr-267 and Tyr-534 sites was analyzed similarly. LAPC-4 cells exhibited the same pattern of AR phosphorylation by these ligands similar to LNCaP cells (Supplementary Figure 1) .
Stimulation of cell proliferation by non-androgen ligands
As cell proliferation requires AR activation in androgen-dependent prostate cancer cells, the effect of these ligands inducing AR phosphorylation on cell proliferation was determined. In LNCaP cells, treatment with EGF, heregulin, Gas6, bombesin or IL-6 all stimulated cell proliferation to similar levels as the androgen dihydrotestosterone ( Figure 2 ). In LAPC-4 cells, all ligands stimulated cell proliferation, although Gas6 and IL-6 were less effective than dihydrotestosterone or other ligands. These results are in agreement with previous reports of stimulation of proliferation in the absence of androgen by heregulin , bombesin (Lee et al., 2001; Desai et al., 2006) or IL-6 (Ueda et al., 2002a) . These data show that these nonandrogen ligands inducing AR phosphorylation promote prostate cancer cell proliferation in the absence of androgen.
Dasatinib inhibits Ack1 kinase activity but does not inhibit EGF-induced AR phosphorylation at Tyr-267
For characterization of signaling pathways and therapeutic applications, a small molecule kinase inhibitor of Ack1 would be desirable. A previous report indicated that dasatinib, a potent inhibitor of Src and Abl kinases, interacted with several additional tyrosine kinases in a competition binding assay, including Ack1 (Carter et al., 2005) . The ability of dasatinib to inhibit Ack1 autophosphorylation as a marker of kinase activity was tested in 293T cells transfected to express activated Ack1 (Figure 3a) . Dasatinib inhibited Ack1 autophosphorylation in a dose-dependent manner, with dasatinib doses of X10 nM demonstrating nearly complete inhibition of Ack1 phosphorylation, consistent with the previously Figure 2 EGF, heregulin, Gas6, bombesin and IL-6 stimulate proliferation of androgen-dependent prostate cancer cell lines in the absence of androgen. Cells were seeded in serum-free medium in triplicate wells of a 96-well plate and treated with EGF (100 ng/ml), heregulin (10 ng/ml), Gas6 (100 ng/ml), IL-6 (10 ng/ml) or bombesin (1 nM) for 72 h. Relative cell proliferation was determined by addition of colorimetric dye WST-8 and measuring absorbance at 450 nM. 
Dasatinib inhibits AR phosphorylation by Ack1
Y Liu et al reported Kd of 6 nM (Carter et al., 2005) . Treatment of LNCaP cells with dasatinib inhibited heregulin-induced Ack1 phosphorylation almost completely at doses of X10 nM (Figure 3b ). Dasatinib treatment inhibited heregulin-induced AR phosphorylation at Tyr-267. The concentration of dasatinib required for the inhibition of AR phosphorylation at Tyr-267 was similar to that required for the inhibition of heregulin-induced Ack1. This result is consistent with the notion that heregulin-induced activation of Ack1 mediates AR phosphorylation at Tyr-267. The effect of dasatinib on EGF-induced phosphorylation of AR was tested. EGFinduced AR phosphorylation at Tyr-534 was inhibited by dasatinib ( Figure 4a ). As dasatinib inhibits Src, this finding is consistent with the idea that Src activation downstream of the EGF receptor leads to AR phosphorylation at Tyr-534. Dasatinib had no effect on EGF-induced AR phosphorylation at Tyr-267, even at doses as high as 1000 nM (Figure 4b ). However, Src activation after EGF treatment was inhibited by dasatinib at a dose as low as 1 nM (Figure 4d ). In LNCaP cells, Ack1 was not activated after EGF treatment, whereas heregulin-induced Ack1 activation was detected (Figure 4c ). These results suggest that at least one other tyrosine kinase (other than Src and Ack1) mediates AR phosphorylation at Tyr-267 after EGF treatment in LNCaP cells and that this kinase (or kinases) is insensitive to dasatinib.
Role of Ack1 and Src in ligand-stimulated AR phosphorylation
To investigate more directly the role of Ack1 or Src in AR phosphorylation after ligand stimulation, the effect of Ack1 or Src knockdown by small interfering RNA (siRNA) was tested ( Figure 5 ). Ack1 knockdown inhibited AR phosphorylation at Tyr-267 induced by heregulin or Gas6 treatment. Src knockdown inhibited AR phosphorylation at Tyr-534 induced by EGF, IL-6 or bombesin treatment. However, EGF-induced AR phosphorylation at Tyr-267 was not inhibited by Ack1 knockdown or Src knockdown, despite markedly reduced expression levels of Ack1 or Src by siRNA 
Effect of dasatinib on Ack1-induced AR activation
The biological effect of dasatinib on prostate cancer cells was investigated. First, LNCaP cells transfected with the AR-dependent reporter ARR2-PB-luciferase were investigated. Treatment of these cells with heregulin or EGF (without androgen) increased luciferase activity. The AR antagonist bicalutamide inhibited androgeninduced AR reporter activity but did not inhibit heregulin-or EGF-induced AR reporter activity (Supplementary Figure 2 ). Therefore, heregulin-or EGFinduced AR activation likely reflects the ligand-independent activation of AR through receptor tyrosine kinase-mediated pathways. Dasatinib treatment inhibited heregulin-induced AR reporter activity with an IC 50 of 4.9 nM, consistent with the hypothesis that the stimulatory effect of heregulin is mediated by downstream Ack1 activation (Figure 6a ). However, dasatinib treatment had no effect on EGF-induced AR reporter activity, even at doses as high as 1000 nM, in contrast to its inhibitory effect on heregulin-mediated AR reporter activity (Figure 6b ). The effect of dasatinib on the expression of endogenous AR target genes, prostatespecific antigen (PSA) and human kallikrein 2 (hK2) (also known as KLK2) was tested. Treatment of LNCaP cells with EGF or heregulin increased PSA and hK2 mRNA levels by 4-6-fold. Dasatinib treatment partially blocked heregulin-induced expression of PSA and hK2 mRNA, but not EGF-induced expression of PSA and hK2 mRNA (Figure 6c and d) . Similar results were seen in LAPC-4 cells (Supplementary Figure 3) . As heregulin-induced Tyr-267 phosphorylation is blocked by dasatinib, but EGF-induced Tyr-267 phosphorylation is not blocked by dasatinib, these results suggest that the stimulatory effect of growth factors on AR is correlated with the induction of Tyr-267 phosphorylation, either by Ack1 or by an unidentified tyrosine kinase downstream of EGF.
Effect of dasatinib on Ack1-induced colony formation and xenograft tumor growth Activated Ack1 enhances the ability of LNCaP cells to form colonies in soft agar and grow as a subcutaneous xenograft tumor in castrated mice (Mahajan et al., 2005 (Mahajan et al., , 2007 . The effect of dasatinib on Ack1-induced colony formation was determined. Dasatinib treatment decreased the number of soft agar colonies in LNCaP cells expressing activated Ack1 in a dose-dependent manner (Figure 7a ). Dasatinib also inhibited soft agar colony growth of LNCaP vector control cells, likely through the inhibition of Src kinase expressed in LNCaP (Park et al., 2008) . We investigated the effect of dasatinib treatment in vivo on the xenograft tumor growth of LNCaP-Ack1 cells in castrated mice. Castrated mice with xenograft tumors were treated with dasatinib orally or vehicle control and the tumor volume was monitored. Administration of dasatinib resulted in significant inhibition of xenograft tumor growth. At days 25 and 29, the tumor volume of the dasatinib treatment group was decreased by B50% compared with that of the control group (Figure 7b ). The Dasatinib inhibits AR phosphorylation by Ack1 Y Liu et al phosphorylation status of Ack1 and AR proteins was determined by immunoblotting protein extracts of harvested tumor tissues at the conclusion of the experiment. In tumors harvested from control animals, Ack1 and AR at Tyr-267 were constitutively phosphorylated, whereas in tumors from dasatinib-treated animals, Ack1 and AR proteins were not phosphorylated (Figure 7c ). These data suggest that inhibition of Ack1 kinase by dasatinib leads to loss of AR phosphorylation and decreased xenograft tumor growth.
Discussion
In this report, we show that Ack1 and Src tyrosine kinases target distinct AR phosphorylation sites (that is, Tyr-267 by Ack1 and Tyr-534 by Src) after activation by cell surface receptors. EGF-, IL-6-and bombesininduced AR phosphorylation at Tyr-534 was inhibited by Src knockdown and dasatinib, a potent Src inhibitor, suggesting Src involvement downstream of these ligands. Activation of AR by EGF and bombesin through Src has been reported previously (Desai et al., 2006; Guo et al., 2006; Kraus et al., 2006) . A recent report indicated that the neuroendocrine-derived peptide parathyroid hormone-related protein stabilizes AR by reducing interaction with the ubiquitin ligase CHIP through Src-mediated phosphorylation of AR at Tyr-534 (DaSilva et al., 2009) . Involvement of Ack1 downstream of heregulin and Gas6 in AR phosphorylation at Tyr-267 was confirmed by Ack1 knockdown as well as dasatinib, which has been shown to be an inhibitor of Ack1 in this study. However, inhibition of Src and Ack1 did not prevent EGF-induced AR tyrosine phosphorylation at Tyr-267, suggesting the existence of an additional unidentified tyrosine kinase (or kinases) capable of phosphorylating AR at Tyr-267 (Figure 8 ). Although identification and understanding the functional role of this kinase on AR signaling will require further work, it is clear that Tyr-267 phosphorylation is involved in some modes of AR transactivation no matter which tyrosine kinase is involved. Inhibition of growth factor-induced AR activity by dasatinib correlates with the loss of AR phosphorylation at Tyr-267, as dasatinib inhibits heregulin-induced AR Tyr-267 phosphorylation and AR reporter activity and target gene expression. In contrast, EGF-induced AR Tyr-267 phosphorylation and AR reporter activity and target gene expression are resistant to dasatinib. This result raises a possibility that phosphorylation of Tyr-267 is required for AR activation downstream of receptor tyrosine kinases. The functional consequences of AR phosphorylation at Tyr-267 and Tyr-534 seem to be similar in that phosphorylation at both sites is linked to enhanced AR recruitment and expression of AR target genes at suboptimal androgen concentrations (Guo et al., 2006; Mahajan et al., 2007) . However, chromatin immuno- precipitation analysis showed that Src-induced AR activation involves AR recruitment preferentially to the proximal promoter elements of the canonical target gene PSA, and that there is no increase in the binding of AR to the distal enhancer wherein androgen-induced and Ack1-driven AR recruitment takes place (Desai et al., 2006; Mahajan et al., 2007; Yang et al., 2009) . Whether this difference in the AR recruitment sites stems from distinct AR phosphorylation sites or possibly due to other components of the transcriptional complex regulated by these kinases is unclear. The differential effect of AR phosphorylation sites on target gene expression and binding of coactivators and corepressors, as well as other proteins involved in the assembly of the active transcriptional complex requires further elucidation.
Dasatinib inhibits a wide spectrum of kinases such as Abl and Src and its ability to inhibit the Bcr-Abl kinase (unmutated and mutated forms) led to its approval for treatment of imatinib-resistant chronic myelogenous leukemia (Brave et al., 2008) . In addition to the ability of Src to promote castration-resistant progression and AR activation, Src is involved in regulating prostate cancer cell migration, invasion and metastasis and affects bone remodeling (Park et al., 2008; Araujo and Logothetis, 2009) . Therefore, dasatinib is currently being studied in the treatment of CRPC as a single agent and in combination with docetaxel chemotherapy Yu et al., 2009) . Our data show that Ack1 kinase is inhibited by dasatinib at clinically relevant concentrations, and preclinical xenograft studies show the feasibility of inhibiting Ack1 in vivo as tumors exhibit loss of constitutive Ack1 and AR phosphorylation after oral treatment with dasatinib. This raises a possibility that dasatinib may show clinical activity against Ack1-driven malignancies. Ack1 binds and is activated by several receptor tyrosine kinases, such as EGFR, HER-2, Mer, Axl, platelet-derived growth factor receptor, LTK (leukocyte receptor tyrosine kinase belonging to the insulin receptor family) and ALK (anaplastic lymphoma kinase) (Mahajan et al., 2005; Galisteo et al., 2006; Pao-Chun et al., 2009) . A recent study has shown that the Ack1 gene is amplified and overexpressed in several tumor types, including CRPC, and this was correlated with cancer progression and poor prognosis (van der Horst et al., 2005) . In addition, Ack1 may also be activated by oncogenic mutations. The current release (version 42) of the Catalogue of Somatic Mutation in Cancer database reported 5 out of 229 tumor samples containing point mutations in Ack1, some of which are likely to lead to constitutive activation of kinase (Forbes et al., 2006) . In a subset of primary CRPC tumor specimens (8 out of 18), the expression of tyrosine-phosphorylated AR and Ack1 was detected by immunoprecipitation and immunoblotting of tumor lysates (Mahajan et al., 2007) . Our findings provide additional mechanisms by which dasatinib may exert antitumor activity in CRPC. Although both Src and Ack1 phosphorylate the AR protein, they target distinct sites. Therefore, phosphoTyr-267 and phospho-Tyr-534 AR expression in CRPC Heregulin and Gas6 activate Ack1 kinase, which leads to AR Tyr-267 phosphorylation. EGF, bombesin and IL-6 activate Src kinase, leading to AR Tyr-534 phosphorylation. In addition, EGF activates an unidentified dasatinib-resistant tyrosine kinase that phosphorylates AR at Tyr-267.
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Y Liu et al tumors may serve as a predictive biomarker of tyrosine kinase inhibitor therapy.
Materials and methods

Cells and reagents
LNCaP cells were obtained from the American Type Culture Collection (Manassas, VA, USA). LAPC-4 cells were provided by Dr Charles Sawyers (Klein et al., 1997) . EGF (R&D Systems, Minneapolis, MN, USA), IL-6 (R&D Systems), Gas6 (R&D Systems) and bombesin (Sigma-Aldrich, St Louis, MO, USA) were purchased. Heregulin was a gift from Genentech (South San Francisco, CA, USA). Dasatinib was obtained from Bristol-Myers-Squibb (Princeton, NJ, USA). Phosphospecific polyclonal antibody against Tyr-267 of AR was generated by a commercial vendor (21st Century Biochemicals, Marlboro, MA, USA). Rabbits were immunized with carrierconjugated phospho-peptides spanning Tyr-267. Immunodepletion using a non-phospho-peptide column and affinity purification using the phospho-peptide column were performed by the vendor. Phospho-specific antibody against Tyr-534 of AR was raised in rabbits using standard methods and affinity purified in a similar manner; its characterization has been reported previously (DaSilva et al., 2009) . A mouse monoclonal antibody against total AR (F39.4.1, Biogenex, San Ramon, CA, USA) was used for immunoblotting. A polyclonal antibody against AR (C-19, Santa Cruz) was used for immunoprecipitation. The antibody against total Ack1 was described previously (Mahajan et al., 2005) . A phosphospecific antibody against Ack1 p-Tyr-284 (# 09-142) was obtained from Millipore (Billerica, MA, USA). Antibodies against total Src (#2108) and phospho-specific Src p-Tyr-416 (#2101) were obtained from Cell Signaling Technology (Beverly, MA, USA).
Transfections and knockdown
Both 293T cells and COS7 cells were transfected with AR or Ack1 or Src expression vectors using Effectene (Qiagen, Valencia, CA, USA) according to the manufacturer's instructions. siRNA sequences against Ack1 were described previously (Mahajan et al., 2007) . For knocking down Src, Validated Stealth RNAi siRNA against Src (Invitrogen, Carlsbad, CA, USA) was used according to the manufacturer's instructions. LNCaP cells were transfected using siPort Lipid (Ambion, Austin, TX, USA) with 100 nM of siRNA or negative control-scrambled siRNA. After 24 h, cells were treated with ligands as indicated. All experiments were repeated at least three times.
Proliferation assays
LNCaP or LAPC-4 cells were seeded at a density of 10 4 cells per well in triplicate in a 96-well plate in serum-free medium (RPMI 1640 for LNCaP and IMDM for LAPC-4). On day 0, cells were treated with dihydrotestosterone (10 nM), EGF (100 ng/ml), heregulin (10 ng/ml), Gas6 (100 ng/ml), bombesin (1 nM) or IL-6 (10 ng/ml). After 3 days of incubation, relative cell proliferation was measured using colorimetric dye WST-8 (Cell Counting Kit-8, Dojindo, Rockville, MD, USA) according to the manufacturer's instructions.
Reporter assays and quantitative reverse-transcription PCR LNCaP cells (8 Â 10 5 cells per 6-cm plate) were transfected with the ARR2-PB-luciferase reporter (500 ng) (Zhang et al., 2000) along with the AR expression vector (50 ng), using Effectene, as described previously (Mahajan et al., 2007) . After overnight incubation, cells were pretreated with dasatinib as indicated for 2 h, then EGF (100 ng/ml) or heregulin (10 ng/ml) for 20 h. Luciferase activity was determined as described previously (Mahajan et al., 2007) . The IC 50 concentration of dasatinib required for inhibition of heregulin-driven luciferase activity was calculated using the dose-response variable slope (four parameters) function of the GraphPad Prism 5 software (GraphPad, La Jolla, CA, USA). For measurement of PSA and hK2 mRNA levels, LNCaP or LAPC-4 cells were incubated in serum-free medium and were pretreated with dasatinib (10 nM) for 2 h, then treated with heregulin (10 ng/ml) or EGF (100 ng/ml) for 20 h. Total RNA was isolated and the mRNA levels of PSA and hK2 were determined by quantitative reverse-transcription PCR, as described previously (Mahajan et al., 2007) .
Colony formation in soft agar
LNCaP cells expressing Ack1 or vector control (10 4 cells per well) were suspended in 0.45% Noble agar along with the indicated concentration of dasatinib and placed above a layer of solidified 0.9% Noble agar in 6-well plates in triplicates. After 3 weeks, colonies were visualized by staining with MTT.
Xenograft tumor growth
LNCaP cells stably expressing activated Ack1 by retroviral transduction have been described previously (Mahajan et al., 2005) . LNCaP-Ack1 cells (2 Â 10 6 ) were mixed with an equal volume of Matrigel (BD Biosciences, Franklin Lakes, NJ, USA) and implanted subcutaneously in the flank of castrated nude male mice, as described previously (Mahajan et al., 2005 (Mahajan et al., , 2007 . When tumors became palpable, mice were randomly divided into two groups. Dasatinib was dissolved in citrate buffer (80 mM, pH 3.1) and administered to mice by oral gavage at a dose of 30 mg/kg twice daily. Tumor size was measured with calipers twice per week. These procedures were approved by the Institutional Animal Use and Care Committee.
Statistical methods
The nonparametric Wilcoxon rank-sum test (using Van der Waerden normal scores) was used for the two-group comparisons of tumor volumes of the treated group (n ¼ 8) with the control group (n ¼ 7) at days 25 and 29 of treatment, respectively. Exact nominal (unadjusted for multiple comparisons) two-sided P-values were reported. Statistical analyses were performed using SAS statistical software, Version 9.2 (SAS Institute Inc., Cary, NC, USA).
